Business Description
Zenas BioPharma Inc
NAICS : 541713
SIC : 2834
Description
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 362.07 | |||||
| Equity-to-Asset | -1.44 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.01 | |||||
| 9-Day RSI | 39.91 | |||||
| 14-Day RSI | 42.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.82 | |||||
| Quick Ratio | 4.82 | |||||
| Cash Ratio | 4.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -112.87 | |||||
| Net Margin % | -109.51 | |||||
| FCF Margin % | -67.34 | |||||
| ROA % | -54.62 | |||||
| ROIC % | -405.46 | |||||
| ROC (Joel Greenblatt) % | -6078.19 | |||||
| ROCE % | -77.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.1 | |||||
| EV-to-EBIT | -8.87 | |||||
| EV-to-EBITDA | -8.89 | |||||
| EV-to-Revenue | 10.02 | |||||
| EV-to-FCF | -15.46 | |||||
| Earnings Yield (Greenblatt) % | -11.27 | |||||
| FCF Yield % | -4.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Zenas BioPharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50 | ||
| EPS (TTM) ($) | -1.02 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 42.49 | ||
| 14-Day ATR ($) | 1.756409 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 16.17 - 20.5 | ||
| Shares Outstanding (Mil) | 39.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zenas BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zenas BioPharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zenas BioPharma Inc Frequently Asked Questions
What is Zenas BioPharma Inc(ZBIO)'s stock price today?
The current price of ZBIO is $17.05. The 52 week high of ZBIO is $20.50 and 52 week low is $16.17.
When is next earnings date of Zenas BioPharma Inc(ZBIO)?
The next earnings date of Zenas BioPharma Inc(ZBIO) is 2024-11-29 Est..
Does Zenas BioPharma Inc(ZBIO) pay dividends? If so, how much?
Zenas BioPharma Inc(ZBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers